Medtronic PLC $MDT Shares Sold by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft lowered its stake in shares of Medtronic PLC (NYSE:MDT) by 58.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 5,000 shares of the medical technology company’s stock after selling 6,990 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Medtronic were worth $480,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in MDT. Lodestone Wealth Management LLC acquired a new stake in shares of Medtronic during the fourth quarter worth approximately $27,000. Anfield Capital Management LLC grew its position in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after buying an additional 230 shares in the last quarter. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic during the third quarter worth approximately $29,000. Board of the Pension Protection Fund acquired a new stake in shares of Medtronic during the fourth quarter worth approximately $29,000. Finally, GoalVest Advisory LLC acquired a new stake in shares of Medtronic during the fourth quarter worth approximately $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

Medtronic stock opened at $76.12 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The company has a market cap of $97.73 billion, a PE ratio of 21.20, a P/E/G ratio of 1.83 and a beta of 0.62. Medtronic PLC has a 12 month low of $74.40 and a 12 month high of $106.33. The company has a fifty day moving average price of $84.76 and a two-hundred day moving average price of $93.64.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts expect that Medtronic PLC will post 5.57 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date was Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Jefferies Financial Group reaffirmed a “hold” rating and issued a $95.00 price objective on shares of Medtronic in a report on Thursday, April 23rd. Robert W. Baird lifted their price objective on shares of Medtronic from $92.00 to $93.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Mizuho decreased their price objective on shares of Medtronic from $125.00 to $120.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. Finally, Argus decreased their price objective on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a report on Monday, April 6th. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $107.80.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).